Feeds

HIV vaccine safe for Phase II human trials

Canadian university claim no adverse effects from first tests

High performance access to file storage

Researchers from the Schulich School of Medicine & Dentistry at Canada's University of Western Ontario have issued a statement saying the first phase of clinical trials of an HIV vaccine have produced “no adverse effects observed including local reactions, signs/symptoms and laboratory toxicities”.

The Reg understands the trial of the vaccine, dubbed'SAV001-H' involved only 40 patients, all of which were HIV-positive. Some of those participating in the trial received a placebo.

The researchers say data from the trial is still being analysed, but say the results they have been able to gather show “significant increase in the HIV-1 antibody formations after SAV001-H administration compared to the base line in some patients.”

That result, along with the lack of adverse effects, sees the researchers declare “we are now prepared to take the next steps towards Phase II and Phase III clinical trials” among a wider population.

The vaccine is described as a a “killed whole virus”, a type of vaccine that uses a genetically-engineered version of the HIV virus that is subjected to chemicals and radiation in ways that allow it to fight HIV without hurting the patient. Such vaccines are already used to treat polio, rabies, influenza and other diseases.

There's still a long way to go before SAV001-H becomes widely available. As the USA's national Institutes of Health explains, Phase II trials use a larger sample to test whether a drug “is effective and to further evaluate its safety” while Phase III trials work with more people again to test “effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.” ®

High performance access to file storage

More from The Register

next story
Elon Musk's LEAKY THRUSTER gas stalls Space Station supply run
Helium seeps from Falcon 9 first stage, delays new legs for NASA robonaut
Red-faced LOHAN team 'fesses up in blown SPEARS fuse fiasco
Standing in the corner, big pointy 'D' hats
KILLER SPONGES menacing California coastline
Surfers are safe, crustaceans less so
LOHAN's Punch and Judy show relaunches Thursday
Weather looking good for second pop at test flights
Discovery time for 200m WONDER MATERIALS shaved from 4 MILLENNIA... to 4 years
Alloy, Alloy: Boffins in speed-classification breakthrough
Curiosity finds not-very-Australian-shaped rock on Mars
File under 'messianic pastries' and move on, people
Top Secret US payload launched into space successfully
Clandestine NRO spacecraft sets off on its unknown mission
Get your MOON GEAR: Auction to feature Space Race memorabilia
Keepsakes from early NASA, Soviet programs up for bids
New FEMTO-MOON sighted BIRTHING from Saturn's RING
Icy 'Peggy' looks to be leaving the outer rings
prev story

Whitepapers

Securing web applications made simple and scalable
In this whitepaper learn how automated security testing can provide a simple and scalable way to protect your web applications.
Five 3D headsets to be won!
We were so impressed by the Durovis Dive headset we’ve asked the company to give some away to Reg readers.
HP ArcSight ESM solution helps Finansbank
Based on their experience using HP ArcSight Enterprise Security Manager for IT security operations, Finansbank moved to HP ArcSight ESM for fraud management.
The benefits of software based PBX
Why you should break free from your proprietary PBX and how to leverage your existing server hardware.
Mobile application security study
Download this report to see the alarming realities regarding the sheer number of applications vulnerable to attack, as well as the most common and easily addressable vulnerability errors.